基于胃黏膜MyD88、ATF2、NF-κB蛋白表达情况分析化浊解毒方加减治疗慢性萎缩性胃炎的机制  

Based on the expression of MyD88,ATF2 and NF-κB proteins in gastric mucosa,the mechanism of Huazujiadu decoction in the treatment of chronic atrophic gastritis was analyzed

作　　者：李金萍 刘阳 李桂云 LI Jinping;LIU Yang;LI Guiyun(Department of Spleen and Stomach Diseases,Shenzhen Hospital,Shanghai University of Traditional Chinese Medicine,Shenzhen Guangdong 518000,China;Department of Geriatric Gastroenterology,Shenzhen Hospital,Shanghai University of Traditional Chinese Medicine,Shenzhen Guangdong 518000,China)

机构地区：[1]上海中医药大学深圳医院脾胃病科,广东深圳518000 [2]上海中医药大学深圳医院老年胃病科,广东深圳518000

出　　处：《四川中医》2024年第9期123-127,共5页Journal of Sichuan of Traditional Chinese Medicine

基　　金：2024年度广东省中医药局科研项目(编号:20241264);2022年罗湖区软科学研究计划项目(编号:LX202202129)。

摘　　要：目的:基于胃黏膜髓样分化因子88(MyD88)、活化复制因子2抗体(ATF2)、核因子-kB(NF-κB)蛋白表达情况分析化浊解毒方加减治疗慢性萎缩性胃炎(CAG)的机制。方法:采用随机数字表法将于2021年1月~2023年5月在上海中医药大学深圳医院接受治疗的120例CAG患者分为A组和B组,每组各60例。A组给予幽门螺杆菌根除三联疗法,B组在A组基础上给予化浊解毒方加减治疗,两组均持续治疗2周。比较两组治疗2周后的临床疗效,治疗前、治疗2周后的胃镜黏膜征象积分、成纤维细胞生长因子23(FGF-23)、白细胞介素-32(IL-32)、降钙素基因相关肽(CGRP)、人表皮生长因子(EGF)、胃黏膜MyD88、ATF2、NF-κB蛋白表达情况,治疗期间的不良反应。结果:B组治疗2周后的总有效率高于A组(88.33%vs 71.67%,P<0.05)。两组治疗2周后的胃镜黏膜征象各项评分均比治疗前低,且与A组比较,B组较低(P<0.05)。两组治疗2周后的血清FGF-23、IL-32、EGF水平均比治疗前低,且与A组比较,B组较低;两组血清CGRP水平比治疗前升高,且与A组比较,B组较高(P<0.05)。两组治疗2周后的胃黏膜MyD88、ATF2、NF-κB蛋白表达均比治疗前低,且与A组比较,B组较低(P<0.05)。B组和A组治疗期间的不良反应发生率比较,差异无统计学意义(5.00%vs 11.67%,P>0.05)。结论:化浊解毒方加减治疗可有效减轻CAG患者胃黏膜炎症反应及胃黏膜损伤程度,分析其机制可能与其能调节胃黏膜MyD88、ATF2、NF-κB蛋白的表达有关,有助于提高治疗效果,且安全性良好。Objective Based on the expression of myeloid differentiation factor 88(MyD88),activated replicator 2 antibody(ATF2)and nuclear factor-KB(NF-κB)protein in gastric mucosa,the mechanism of Huozhuojidofang in the treatment of chronic atrophic gastritis(CAG)was analyzed.Methods A total of 120 patients with CAG admitted to Shenzhen Hospital of Shanghai University of Traditional Chinese Medicine from January 2021 to May 2023 were divided into the group A and the group B by random number table method,60 cases in each group.The group A was given triple therapy of Helicobacter pylori eradication,and the group B was given addition and subtraction of Huazujiedu prescription on the basis of the group A.Both groups were treated for 2 weeks.The clinical efficacy after 2 weeks of treatment.Score of castroscopic mucosal sign,fibroblast growth factor 23(FGF-23),interleukin-32(IL-32),calcitonin gene-related peptide(CGRP),human epidermal growth factor(EGF),gastric mucosa MyD88,ATF2,NF-κB protein expression before and after 2 weeks of treatment,and adverse reactions during treatment of the two groups were compared.Results The rate of total effective in the group B after 2 weeks of treatment was higher than the group A(88.33%vs 71.67%,P<0.05).The scores of gastroscopy mucosal signs after 2 weeks of treatment were lower than before treatment,and compared with the group A,the group B was lower(P<0.05).The levels of serum FGF-23,IL-32 and EGF in two groups after 2 weeks of treatment were lower than before treatment,and compared with the group A,the group B was lower;the levels of serum CGRP in both groups after 2 weeks of treatment was higher than before treatment,and compared with the group A,the group B was higher(P<0.05).The expressions of MyD88,ATF2 and NF-κB protein in gastric mucosa of two groups after 2 weeks of treatment were lower than before treatment,and compared with the group A,the group B were lower(P<0.05).there was no statistical significance of the incidence of adverse reactions during treatment between the group B an

关 键 词：慢性萎缩性胃炎 化浊解毒方 胃黏膜 髓样分化因子88 活化复制因子2抗体 核因子-KB 

分 类 号：R573.32[医药卫生—消化系统]